The macrophage - A novel system to deliver gene therapy to pathological hypoxia

Gene Therapy

Volumn 7, Issue 3, 2000, Pages 255-262

  Griffiths, L ^a   Binley, K ^a   Iqball, S ^a   Kan, O ^a   Maxwell, P ^b   Ratcliffe, P ^c   Lewis, C ^d   Harris, A ^c   Kingsman, S ^a,e   Naylor, S ^a  

^a OXFORD BIOMEDICA UK LTD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adenovirus; Cyclophosphamide; Cytochrome P450; Gene delivery; Hypoxia; Macrophage

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HYPOXIA; MACROPHAGE; PRIORITY JOURNAL; TUMOR;

EID: 0033998433     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301058     Document Type: Article

References (27)

1. Normann SJ. Macrophage infiltration and tumour progression. Cancer Metast Rev 1985; 4: 277-291.
2. Polverini PJ. Role of the macrophage in angiogenesis. In: Goldberg ID, Rosen EM (eds). Regulation of Angiogenesis. Birkhaüser Verlag: Basel, 1997, pp 11-28.
3. Andreesen R et al. Adoptive transfer of tumour cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res 1990; 50: 7450-7456.
4. Jounaidi Y, Hecht JED, Waxman DJ. Retroviral transfer of cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res 1998; 58: 4391-4401.
5. Leek RD et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1997; 56: 4625-4629.
6. Negus RP, Turner L, Burke F, Balkwill FR. Hypoxia down-regulates MCP-1 expression: implications for macrophage distribution in tumours. J Leukoc Biol 1998; 8: 75-88.
7. Rockwell S, Knisely JPS. Hypoxia and angiogenesis in experimental tumour models: therapeutic implications. In: Goldberg ID, Rosen EM (eds). Regulation of Angiogenesis. Birkhaüser Verlag: Basel, 1997, pp 335-360.
8. Wenger RH, Gassman M. Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem 1997; 378: 609-616.
9. Dachs GU et al. Targeting gene expression to hypoxic tumour cells. Nature Meet 1997; 3: 515-520.
10. Knighton DR et al. Oxygen tension regulates the expression of angiogenesis factor by macrophages. Science 1983; 221: 1283-1285.
11. Scannell G et al. Hypoxia induces a human macrophage cell line to release tumour necrosis factor-alpha and its soluble receptors in vitro. J Surg Res 1993; 54: 281-285.
12. Albina JE et al. Macrophage activation by culture in an anoxic environment. J Immunol 1995; 155: 4391-4396.
13. Melillo G et al. Functional requirement of the hypoxia-responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine. J Biol Chem 1997; 272: 12236-12243.
14. Harmey JH et al. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol 1998; 5: 271-278.
15. Binley K et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Therapy 1999; 6: 1721-1727.
16. Sutherland RM. Cell and environment interactions in tumour microregions: the multicell spheroid model. Science 1990; 240: 177-184.
17. Maxwell PH, Pugh CW, Ratcliffe PJ. Inducible operation of the erythropoietin 3′ enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. Proc Natl Acad Sci USA 1993; 90: 2423-2427.
18. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997; 11: 72-82.
19. Wiesener MS et al. Induction of endothelial PAS domain protein1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1 alpha. Blood 1998; 92: 2260-2268.
20. Wickham TJ, Carrion ME, Kovesdi I. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Therapy 1995; 2: 750-756.
21. Naldini L et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
22. Andreesen R, Hennemann B, Krause SW. Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. J Leukoc Biol 1998; 64: 419-426.
23. Brizel DM et al. Tumour hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38: 285-289.
24. Bugelski PJ et al. Recruitment of exogenous macrophages into metastases at different stages of tumour growth. Cancer Immunol Immunother 1987; 24: 93-98.
25. Bilbao G et al. Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo. FASEB J 1997; 11: 624-634.
26. Firth JD, Ebert BL, Pugh CW, Ratcliffe PJ. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3′ enhancer. Proc Natl Acad Sci USA 1994; 91: 6496-6500.
27. Lowenstein PR, Enquist LW. Protocols for Gene Transfer in Neuroscience: Towards Gene Therapy of Neurological Disorders. John Wiley: New York, 1996.